Delcath Systems (DCTH) Competitors

$11.09 +0.02 (+0.18%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$11.18 +0.09 (+0.81%)

As of 05/18/2026 04:10 PM Eastern

DCTH vs. ENOV, PLSE, KMTS, INSP, and AVNS

Should you buy Delcath Systems stock or one of its competitors? MarketBeat compares Delcath Systems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Delcath Systems include Enovis (ENOV), Pulse Biosciences (PLSE), Kestra Medical Technologies (KMTS), Inspire Medical Systems (INSP), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry.

How does Delcath Systems compare to Enovis?

Delcath Systems (NASDAQ:DCTH) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Delcath Systems has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Enovis has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Enovis	-49.92%	10.32%	4.57%

In the previous week, Delcath Systems had 8 more articles in the media than Enovis. MarketBeat recorded 11 mentions for Delcath Systems and 3 mentions for Enovis. Enovis' average media sentiment score of 0.57 beat Delcath Systems' score of -0.45 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Delcath Systems currently has a consensus target price of $22.50, indicating a potential upside of 102.89%. Enovis has a consensus target price of $45.17, indicating a potential upside of 78.81%. Given Delcath Systems' higher possible upside, equities analysts clearly believe Delcath Systems is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Delcath Systems has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.49	$2.70M	$0.01	1,109.00
Enovis	$2.25B	0.65	-$1.18B	-$19.88	N/A

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Enovis beats Delcath Systems on 9 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Pulse Biosciences currently has a consensus target price of $30.00, suggesting a potential upside of 17.14%. Delcath Systems has a consensus target price of $22.50, suggesting a potential upside of 102.89%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Delcath Systems had 6 more articles in the media than Pulse Biosciences. MarketBeat recorded 11 mentions for Delcath Systems and 5 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.84 beat Delcath Systems' score of -0.45 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Delcath Systems has a net margin of 0.62% compared to Pulse Biosciences' net margin of 0.00%. Delcath Systems' return on equity of 0.51% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Delcath Systems	0.62%	0.51%	0.46%

Pulse Biosciences has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Delcath Systems has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,064.19	-$72.78M	-$1.10	N/A
Delcath Systems	$85.23M	4.49	$2.70M	$0.01	1,109.00

Summary

Delcath Systems beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Delcath Systems (NASDAQ:DCTH) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Delcath Systems has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.49	$2.70M	$0.01	1,109.00
Kestra Medical Technologies	$59.81M	19.12	-$113.81M	-$3.96	N/A

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 3.6% of Kestra Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Delcath Systems currently has a consensus price target of $22.50, indicating a potential upside of 102.89%. Kestra Medical Technologies has a consensus price target of $27.40, indicating a potential upside of 39.87%. Given Delcath Systems' stronger consensus rating and higher probable upside, research analysts clearly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Delcath Systems had 8 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 11 mentions for Delcath Systems and 3 mentions for Kestra Medical Technologies. Kestra Medical Technologies' average media sentiment score of 0.63 beat Delcath Systems' score of -0.45 indicating that Kestra Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Delcath Systems has a net margin of 0.62% compared to Kestra Medical Technologies' net margin of -171.87%. Delcath Systems' return on equity of 0.51% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%

Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Inspire Medical Systems?

Delcath Systems (NASDAQ:DCTH) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Inspire Medical Systems has a net margin of 14.33% compared to Delcath Systems' net margin of 0.62%. Inspire Medical Systems' return on equity of 10.35% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Inspire Medical Systems	14.33%	10.35%	8.81%

Inspire Medical Systems has higher revenue and earnings than Delcath Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.49	$2.70M	$0.01	1,109.00
Inspire Medical Systems	$911.98M	1.32	$145.42M	$4.49	9.31

Delcath Systems has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Delcath Systems currently has a consensus price target of $22.50, suggesting a potential upside of 102.89%. Inspire Medical Systems has a consensus price target of $85.00, suggesting a potential upside of 103.38%. Given Inspire Medical Systems' higher probable upside, analysts plainly believe Inspire Medical Systems is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Inspire Medical Systems	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.10

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Delcath Systems had 8 more articles in the media than Inspire Medical Systems. MarketBeat recorded 11 mentions for Delcath Systems and 3 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 0.06 beat Delcath Systems' score of -0.45 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspire Medical Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inspire Medical Systems beats Delcath Systems on 10 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Delcath Systems has a consensus target price of $22.50, indicating a potential upside of 102.89%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 2.3% of Avanos Medical shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Delcath Systems has a net margin of 0.62% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Delcath Systems	0.62%	0.51%	0.46%

Avanos Medical has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Delcath Systems has lower revenue, but higher earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$701.20M	1.65	-$72.90M	-$1.61	N/A
Delcath Systems	$85.23M	4.49	$2.70M	$0.01	1,109.00

In the previous week, Delcath Systems had 11 more articles in the media than Avanos Medical. MarketBeat recorded 11 mentions for Delcath Systems and 0 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 0.00 beat Delcath Systems' score of -0.45 indicating that Avanos Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Avanos Medical	Neutral
Delcath Systems	Neutral

Summary

Delcath Systems beats Avanos Medical on 10 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$382.15M	$6.75B	$6.25B	$12.29B
Dividend Yield	N/A	1.76%	2.80%	5.30%
P/E Ratio	1,109.00	49.87	20.86	25.23
Price / Sales	4.49	82.63	550.91	75.54
Price / Cash	211.77	24.43	27.48	37.30
Price / Book	3.52	6.54	9.67	6.63
Net Income	$2.70M	$158.81M	$3.56B	$335.59M
7 Day Performance	-2.20%	-1.40%	-1.69%	-1.20%
1 Month Performance	2.12%	-5.70%	-2.65%	-1.16%
1 Year Performance	-38.73%	-4.89%	30.03%	28.10%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	1.9752 of 5 stars	$11.09 +0.2%	$22.50 +102.9%	-35.1%	$382.15M	$85.23M	1,109.00	60
ENOV Enovis	4.1733 of 5 stars	$25.93 +4.7%	$45.17 +74.2%	-30.0%	$1.49B	$2.28B	N/A	7,802
PLSE Pulse Biosciences	2.3828 of 5 stars	$21.74 +13.9%	$30.00 +38.0%	+49.0%	$1.48B	$350K	N/A	140
KMTS Kestra Medical Technologies	2.2019 of 5 stars	$21.58 -1.2%	$27.40 +27.0%	-20.4%	$1.26B	$59.81M	N/A	300	Positive News Insider Trade
INSP Inspire Medical Systems	3.7558 of 5 stars	$43.13 -0.5%	$85.00 +97.1%	-72.6%	$1.24B	$911.98M	9.61	1,333

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. ENOV, PLSE, KMTS, INSP, and AVNS

How does Delcath Systems compare to Enovis?

Summary

How does Delcath Systems compare to Pulse Biosciences?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

How does Delcath Systems compare to Inspire Medical Systems?

Summary

How does Delcath Systems compare to Avanos Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. ENOV, PLSE, KMTS, INSP, and AVNS

How does Delcath Systems compare to Enovis?

Which has more risk & volatility, DCTH or ENOV?

Is DCTH or ENOV more profitable?

Does the media prefer DCTH or ENOV?

Do analysts recommend DCTH or ENOV?

Which has better valuation & earnings, DCTH or ENOV?

Do insiders and institutionals have more ownership in DCTH or ENOV?

Summary

How does Delcath Systems compare to Pulse Biosciences?

Do analysts prefer PLSE or DCTH?

Do insiders and institutionals believe in PLSE or DCTH?

Does the media favor PLSE or DCTH?

Is PLSE or DCTH more profitable?

Which has more risk and volatility, PLSE or DCTH?

Which has stronger earnings & valuation, PLSE or DCTH?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Which has better valuation and earnings, DCTH or KMTS?

Do institutionals and insiders have more ownership in DCTH or KMTS?

Do analysts rate DCTH or KMTS?

Does the media refer more to DCTH or KMTS?

Is DCTH or KMTS more profitable?

Which has more risk & volatility, DCTH or KMTS?

Summary

How does Delcath Systems compare to Inspire Medical Systems?

Is DCTH or INSP more profitable?

Which has preferable valuation & earnings, DCTH or INSP?

Which has more risk & volatility, DCTH or INSP?

Do analysts prefer DCTH or INSP?

Do institutionals & insiders hold more shares of DCTH or INSP?

Does the media favor DCTH or INSP?

Summary

How does Delcath Systems compare to Avanos Medical?

Do analysts prefer AVNS or DCTH?

Do institutionals and insiders have more ownership in AVNS or DCTH?

Is AVNS or DCTH more profitable?

Which has more risk and volatility, AVNS or DCTH?

Which has preferable earnings and valuation, AVNS or DCTH?

Does the media prefer AVNS or DCTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools